ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile.
about
Cytokine production associated with smallpox vaccine responsesSmallpox: can we still learn from the journey to eradication?Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infectionSide-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primatesAntibodies for biodefenseModeling the Effect of Herd Immunity and Contagiousness in Mitigating a Smallpox Outbreak.Deaths following vaccination: What does the evidence show?Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors.HLA alleles associated with the adaptive immune response to smallpox vaccine: a replication studySmallpox vaccine safety is dependent on T cells and not B cellsEnhancement of immune response to an antigen delivered by vaccinia virus by displaying the antigen on the surface of intracellular mature virion.A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination.Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAsA Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis.Edward jenner and the small pox vaccine.Ectromelia Virus Disease Characterization in the BALB/c Mouse: A Surrogate Model for Assessment of Smallpox Medical CountermeasuresMetabolites as biomarkers of adverse reactions following vaccination: A pilot study using nuclear magnetic resonance metabolomics.Oncolytic vaccinia virus for the treatment of cancer.The strategic use of novel smallpox vaccines in the post-eradication world.Unintentional transfer of vaccinia virus associated with smallpox vaccines: ACAM2000(®) compared with Dryvax(®).Replicating poxviruses for human cancer therapy.Myocarditis and the military patient.Pericarditis and pericardial effusions in the military patient.Defending against smallpox: a focus on vaccines.Vaccination with a codon-optimized A27L-containing plasmid decreases virus replication and dissemination after vaccinia virus challenge.Vaccinia Virus Natural Infections in Brazil: The Good, the Bad, and the Ugly.Enhancing health care worker ability to detect and care for patients with monkeypox in the Democratic Republic of the Congo.Challenges and Achievements in Prevention and Treatment of Smallpox.Disaster Preparedness: Biological Threats and Treatment Options.Characterization of the immune response elicited by the vaccinia virus L3 protein delivered as naked DNA.A Critical Analysis of the Scientific and Commercial Rationales for the De Novo Synthesis of Horsepox Virus.Recurrence of pericarditis after influenza vaccination: a case report and review of the literature.
P2860
Q26823501-8133EB4B-8183-4772-909E-F7683CA6646CQ26991932-9FF0A6D7-C311-4A7C-9452-1A0FDBD8C12DQ27321985-40293759-FDC4-43EC-8FD2-BEF5DBF3987EQ27325586-716894CD-3AEE-4C13-A4C2-A4583FA29D11Q28394941-E9961EAC-EAC4-402B-885A-FBF9AC423C51Q30205740-09E1B564-5651-4A0E-8D04-D07AB6829E7DQ33165769-7776E850-07F2-41D0-B1CF-E0D3C74FDF33Q33936717-0E6959E0-EFD8-47D3-81A8-8D9DE072783EQ34024252-B0A93273-8402-4709-B4E9-5E1F6F3120B1Q34743303-322B7B9F-5037-40EB-B740-88A7071A7D82Q35113336-9A2178A9-5D25-47E9-8FB2-D07ED0E9EB04Q35202813-5F31EA11-83FC-4279-8563-EF2FA0223E42Q35571248-2E3CBEEC-DB67-4B64-9674-71A42EC55FF0Q35634159-3586C43A-D5B5-4F9D-978A-265CB38B63BBQ35800226-A4301F22-74CC-4A48-ACFE-6F1705F3672EQ35928306-9BDA40C0-6094-4D0A-AC84-FEE6F888DD69Q37153772-12F20568-7288-4067-AE7D-08CDB78B7269Q37695939-1681D8E6-3792-48AE-B67C-89DFC9C2D2B1Q37845399-7DCD4113-3B59-4CA5-9754-E73DDC30E76DQ37909421-2DB3A941-AB10-466A-B6E7-3E26952D41B4Q38097615-8E56B604-4155-4B28-8A1F-44B33FF0E566Q38407351-06CE80CA-8189-43A8-AE84-88D1D5B7E8FBQ38561472-CA9416E7-BFB6-4678-AD7A-CDC8F3C8455CQ38562295-5F9BA01B-BE36-432F-B88E-EAF524163165Q38799357-3E1ECC7C-0497-4976-9419-3C3D13C29105Q40153814-9075F394-8CA9-4E0B-BA6C-A1040166EBCCQ45324824-8F892488-A040-4A74-BA25-7C5D7BF1930EQ46579432-DF3AD064-815F-4254-A183-75CE41CF5C12Q47547852-6B0CD667-965B-479A-8927-6A7AEFD93DE1Q47558565-EDDFF6EE-C766-4A3C-94EF-A898888A49A2Q52662745-DC0CDD15-FA9F-4F73-B887-CF4144F263B3Q54250130-7B2B224D-0AA0-435D-8B90-791C16B47C3BQ55261109-04A5838E-EB0F-42A7-A7D0-876DE624C761
P2860
ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile.
@ast
ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile.
@en
type
label
ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile.
@ast
ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile.
@en
prefLabel
ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile.
@ast
ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile.
@en
P2860
P921
P356
P1476
ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile.
@en
P2093
Aysegul Nalca
Elizabeth E Zumbrun
P2860
P356
10.2147/DDDT.S3687
P407
P577
2010-05-25T00:00:00Z